| Sep to Dec 2027Quarter disclosed | SAR445399 | SNY | Topline readout | Hidradenitis Suppurativa | Scheduled | ClinicalTrials.gov |
| September 2027Month disclosed | pcv21 vaccine (PCV21) | SNY | Primary completion | Pneumococcal Immunization | Scheduled | ClinicalTrials.gov |
| September 2027Month disclosed | SAR445399 | SNY | Primary completion | Hidradenitis Suppurativa | Scheduled | ClinicalTrials.gov |
| September 2027Month disclosed | amlitelimab (SAR445229) | SNY | Primary completion | Dermatitis Atopic | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | Dupixent (dupilumab) | SNY | Topline readout | Prurigo Nodularis | Scheduled | ClinicalTrials.gov |
| Oct 2027 to Jan 2028Quarter disclosed | pcv21 vaccine (PCV21) | SNY | Topline readout | Pneumococcal Immunization | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | pcv21 vaccine (PCV21) | SNY | Primary completion | Pneumococcal Immunization | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | Dupixent (dupilumab) | SNY | Primary completion | Prurigo Nodularis | Scheduled | ClinicalTrials.gov |
| October 2027Month disclosed | SAR445399 | SNY | Primary completion | Non-cystic Fibrosis Bronchiectasis | Delayed | ClinicalTrials.gov |
| Nov 2027 to Feb 2028Quarter disclosed | Wayrilz (rilzabrutinib) | SNY | Topline readout | Immune Thrombocytopenia | Scheduled | ClinicalTrials.gov |
| November 2027Month disclosed | Wayrilz (rilzabrutinib) | SNY | Primary completion | Immune Thrombocytopenia | Scheduled | ClinicalTrials.gov |
| Dec 2027 to Mar 2028Quarter disclosed | iiv-hd (standalone) | SNY | Topline readout | Immunization; Healthy Volunteers; COVID-19 Immunization | Scheduled | ClinicalTrials.gov |
| December 2027Month disclosed | iiv-hd (standalone) | SNY | Primary completion | Immunization; Healthy Volunteers; COVID-19 Immunization | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | sarilumab sar153191 (regn88) (SAR153191) | SNY | Primary completion | Juvenile Idiopathic Arthritis | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | sarilumab sar153191 (regn88) (SAR153191) | SNY | Topline readout | Juvenile Idiopathic Arthritis | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | frexalimab (SAR441344) | SNY | Topline readout | Multiple Sclerosis | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | TZIELD® (teplizumab) | SNY | Topline readout | Type 1 Diabetes Mellitus | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2028Quarter disclosed | menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) | SNY | Topline readout | Meningococcal Infection; Healthy Volunteers | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | TZIELD® (teplizumab) | SNY | Primary completion | Type 1 Diabetes Mellitus | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) | SNY | Primary completion | Meningococcal Infection; Healthy Volunteers | Scheduled | ClinicalTrials.gov |
| March 2028Month disclosed | frexalimab (SAR441344) | SNY | Primary completion | Multiple Sclerosis | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | Wayrilz (rilzabrutinib) | SNY | Topline readout | Autoimmune Haemolytic Anaemia | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | dupilumab coformulated with berahyaluronidase alfa | SNY | Topline readout | Dermatitis Atopic | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | dupilumab coformulated with berahyaluronidase alfa | SNY | Primary completion | Dermatitis Atopic | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| May 2028Month disclosed | Wayrilz (rilzabrutinib) | SNY | Primary completion | Autoimmune Haemolytic Anaemia | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | SAR447537 | SNY | Topline readout | Alpha 1-Antitrypsin Deficiency; Emphysema | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | TZIELD® (teplizumab) | SNY | Topline readout | Type 1 Diabetes Mellitus | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | Wayrilz (rilzabrutinib) | SNY | Topline readout | Immunoglobulin G4 Related Disease | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2028Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Hidradenitis | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | TZIELD® (teplizumab) | SNY | Primary completion | Type 1 Diabetes Mellitus | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Hidradenitis | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | Wayrilz (rilzabrutinib) | SNY | Primary completion | Immunoglobulin G4 Related Disease | Scheduled | ClinicalTrials.gov |
| June 2028Month disclosed | SAR447537 | SNY | Primary completion | Alpha 1-Antitrypsin Deficiency; Emphysema | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | acne mrna (messenger ribonucleic acid) vaccine | SNY | Topline readout | Acne | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2028Quarter disclosed | bivalent rsv+hmpv protein vaccine (RPF08203) | SNY | Topline readout | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | bivalent rsv+hmpv protein vaccine (RPF08203) | SNY | Primary completion | Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers | Scheduled | ClinicalTrials.gov |
| July 2028Month disclosed | acne mrna (messenger ribonucleic acid) vaccine | SNY | Primary completion | Acne | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2028Quarter disclosed | SAR445877 | SNY | Topline readout | Gastric Cancer; Oesophageal Carcinoma | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | SAR445877 | SNY | Primary completion | Gastric Cancer; Oesophageal Carcinoma | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | belumosudil (SAR445761) | SNY | Topline readout | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | belumosudil (SAR445761) | SNY | Topline readout | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | belumosudil (SAR445761) | SNY | Primary completion | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | belumosudil (SAR445761) | SNY | Primary completion | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | isatuximab intravenous (iv) | SNY | Topline readout | Plasma Cell Myeloma | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | isatuximab intravenous (iv) | SNY | Primary completion | Plasma Cell Myeloma | Scheduled | ClinicalTrials.gov |
| Dec 2028 to Mar 2029Quarter disclosed | Dupixent (dupilumab) | SNY | Topline readout | Wheezing; Asthma | Scheduled | ClinicalTrials.gov |
| December 2028Month disclosed | Dupixent (dupilumab) | SNY | Primary completion | Wheezing; Asthma | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | amlitelimab (SAR445229) | SNY | Topline readout | Dermatitis Atopic | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | belumosudil (SAR445761) | SNY | Topline readout | Lung Transplant Rejection | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | amlitelimab (SAR445229) | SNY | Primary completion | Dermatitis Atopic | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | belumosudil (SAR445761) | SNY | Primary completion | Lung Transplant Rejection | Scheduled | ClinicalTrials.gov |
| Feb to May 2029Quarter disclosed | lunsekimig (SAR443765) | SNY | Topline readout | Chronic Rhinosinusitis With Nasal Polyps | Scheduled | ClinicalTrials.gov |
| February 2029Month disclosed | lunsekimig (SAR443765) | SNY | Primary completion | Chronic Rhinosinusitis With Nasal Polyps | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | tolebrutinib (SAR442168) | SNY | Topline readout | — | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | tolebrutinib (SAR442168) | SNY | Primary completion | — | Scheduled | ClinicalTrials.gov |
| May to Aug 2029Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| May 2029Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Jun to Sep 2029Quarter disclosed | Kevzara (sarilumab) | SNY | Topline readout | Polymyalgia Rheumatica | Scheduled | ClinicalTrials.gov |
| June 2029Month disclosed | Kevzara (sarilumab) | SNY | Primary completion | Polymyalgia Rheumatica | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | SAR448851 | SNY | Topline readout | Dementia, Alzheimer's Type; Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | SAR448851 | SNY | Primary completion | Dementia, Alzheimer's Type; Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | duvakitug (TEV-48574) | SNY | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | Qfitlia™ (fitusiran) | SNY | Topline readout | Hemophilia | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | frexalimab (SAR441344) | SNY | Topline readout | Kidney Transplant Rejection | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | Qfitlia™ (fitusiran) | SNY | Primary completion | Hemophilia | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | duvakitug (TEV-48574) | SNY | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | frexalimab (SAR441344) | SNY | Primary completion | Kidney Transplant Rejection | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2029Quarter disclosed | belumosudil (SAR445761) | SNY | Topline readout | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| September 2029Month disclosed | belumosudil (SAR445761) | SNY | Primary completion | Chronic Graft Versus Host Disease | Scheduled | ClinicalTrials.gov |
| Oct 2029 to Jan 2030Quarter disclosed | riliprubart prefilled pen (pfp) (SAR445088) | SNY | Topline readout | Polyneuropathy, Inflammatory Demyelinating, Chronic | Scheduled | ClinicalTrials.gov |
| October 2029Month disclosed | riliprubart prefilled pen (pfp) (SAR445088) | SNY | Primary completion | Polyneuropathy, Inflammatory Demyelinating, Chronic | Scheduled | ClinicalTrials.gov |
| Nov 2029 to Feb 2030Quarter disclosed | lunsekimig (SAR443765) | SNY | Topline readout | Chronic Obstructive Pulmonary Disease | Scheduled | ClinicalTrials.gov |
| Nov 2029 to Feb 2030Quarter disclosed | lunsekimig (SAR443765) | SNY | Topline readout | Chronic Obstructive Pulmonary Disease | Scheduled | ClinicalTrials.gov |
| November 2029Month disclosed | lunsekimig (SAR443765) | SNY | Primary completion | Chronic Obstructive Pulmonary Disease | Scheduled | ClinicalTrials.gov |
| November 2029Month disclosed | lunsekimig (SAR443765) | SNY | Primary completion | Chronic Obstructive Pulmonary Disease | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | Cerezyme (imiglucerase) | SNY | Topline readout | Gaucher's Disease Type III | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | Cerezyme (imiglucerase) | SNY | Primary completion | Gaucher's Disease Type III | Scheduled | ClinicalTrials.gov |
| Oct 2030 to Jan 2031Quarter disclosed | isatuximab sar650984 (SAR650984) | SNY | Topline readout | Plasma Cell Myeloma | Scheduled | ClinicalTrials.gov |
| October 2030Month disclosed | isatuximab sar650984 (SAR650984) | SNY | Primary completion | Plasma Cell Myeloma | Scheduled | ClinicalTrials.gov |